NY-CALVIN-KLEIN-INC
3.8.2020 13:02:08 CEST | Business Wire | Press release
Calvin Klein, Inc., a wholly owned subsidiary of PVH Corp. [NYSE: PVH], and Calvin Klein Fragrances, a division of Coty Inc. [NYSE: COTY], today revealed the worldwide global advertising campaign for ETERNITY Calvin Klein with the return of maternal health activist and model Christy Turlington Burns, alongside her husband, director, writer, producer and actor Edward Burns, as the faces of the ETERNITY campaign.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200803005090/en/
ETERNITY Calvin Klein advertising has artfully and unforgettably captured the promise of romance, intimacy, and commitment. Together, Turlington Burns who starred in the first ETERNITY advertising campaign when it debuted in 1988, and Burns who has appeared next to his wife in the 2014 and 2016 campaigns, bring to life the essence of the ETERNITY love story with their timeless relationship.
Today, the ETERNITY story continues with the iconic couple in a new television and print campaign that portrays an enduring love rooted in sensuality, authenticity, spontaneity, and supports the launch of the new ETERNITY Cologne for him and ETERNITY Eau Fresh for her Calvin Klein.
“After shooting the first ETERNITY Calvin Klein campaign ever over 30 years ago, it’s a pleasure to be working with Calvin Klein again and to continue to be a part of the history of such an iconic fragrance,” said Turlington Burns + Burns jointly. “We are honored to be part of this new campaign celebrating our relationship with ETERNITY Calvin Klein.”
The television campaign is captured by filmmaker and photographer Matt Lambert and is a combination of traditional black and white in addition to color shots. This juxtaposition conveys their committed past with the strength of their present relationship. The campaign, a compilation of joyful moments by the ocean, is an homage to their love story and is set to a reimagined cover of the iconic love song ‘Unchained Melody’ by Lykke Li.
Lachlan Bailey photographed the iconic couple in a classic black and white still campaign visual on the beach. Turlington Burns' hair is effortlessly being swept back by the ocean breeze while Burns adoringly pulls her toward him. The image is just one of many memories in time for the couple, a stolen moment in their endless love story.
“We are thrilled to welcome back such an iconic couple to celebrate the next chapter of ETERNITY Calvin Klein which continues its legacy as one of the most beloved fragrances for both men and women,” said Simona Cattaneo, President of Luxury Brands at Coty. “With this new campaign ETERNITY continues to inspire timeless love; its romantic values are undimmed by the passing of time and still resonate with consumers today.”
In addition to supporting ETERNITY Calvin Klein Signature, the campaign also supports the new line extension ETERNITY Cologne for him and ETERNITY Eau Fresh for her Calvin Klein through the still campaign visual also shot by Bailey. The hero image is an injection of happiness and bursts of freshness; Turlington Burns and Burns are captured playfully frolicking in the ocean, holding each other closely as the waves splash around them.
Evoking the free-spirited nature of the ocean and the joy of strolling through a beautiful sensual garden, the line extension inspires spontaneity while celebrating the spirit of eternal love. The enduring legacy of the ETERNITY Calvin Klein Signature is playfully reimagined for modern lovers with fresh green ingredients in ETERNITY Cologne for him Calvin Klein by perfumers Julie Massé, Ralf Schwieger and Véronique Nyberg of Mane and romantic watery florals in ETERNITY Eau Fresh for her Calvin Klein by perfumers Olivier Gillotin and Sonia Constant of Givaudan.
ETERNITY Cologne for him and ETERNITY Eau Fresh for her Calvin Klein are available for sale globally starting today on a rolling basis.
About Calvin Klein, Inc.:
CALVIN KLEIN is a global lifestyle brand that exemplifies bold, progressive ideals and a seductive aesthetic. We seek to thrill and inspire our audience while using provocative imagery and striking designs to ignite the senses.
Founded in 1968 by Calvin Klein and his business partner Barry Schwartz, we have built our reputation as a leader in American fashion through our clean aesthetic and innovative designs. Global retail sales of CALVIN KLEIN brand products exceeded $9 billion in 2019 and were distributed in over 110 countries. Calvin Klein employs over 11,500 associates globally. We were acquired by PVH Corp. in 2003.
About COTY Inc.
Coty is one of the world’s largest beauty companies with approximately $9 billion in revenue, with a purpose to celebrate and liberate the diversity of consumers’ beauty. Its strong entrepreneurial heritage has created an iconic portfolio of leading beauty brands. Coty is the global leader in fragrance, a strong number two in professional salon hair color & styling, and number three in color cosmetics. Coty operates three divisions – Coty Consumer Beauty, which is focused on color cosmetics, retail hair coloring and styling products, body care and mass fragrances sold primarily in the mass retail channels with brands such as Bourjois, Max Factor, Rimmel, Wella, Adidas and Guess; Coty Luxury, which is focused on prestige fragrances and skincare with brands such as Gucci, Hugo Boss, Calvin Klein, Chloe, Bottega Veneta and Alexander McQueen; and Coty Professional Beauty, which is focused on servicing salon owners and professionals in both hair and nail, with brands such as Wella Professionals, System Professional, OPI and ghd. Coty has approximately 20,000 colleagues globally and its products are sold in over 130 countries. Coty and its brands are committed to a range of social causes as well as seeking to minimize its impact on the environment. For additional information about Coty Inc., please visit www.coty.com .
ADVERTISING CREDITS:
Creative Direction: Calvin Klein and Mazarine
Campaign Videos: Matt Lambert
Advertising Campaign images: Lachlan Bailey
EDITORIAL CREDIT:
ETERNITY For Women Eau de Parfum CALVIN KLEIN
ETERNITY For Men Eau de toilette CALVIN KLEIN
ETERNITY Eau Fresh for her CALVIN KLEIN
ETERNITY Cologne for him CALVIN KLEIN
TVC: https://youtu.be/NN9Q2pKiDKE
SOCIAL MEDIA: #cketernity
BRAND HANDLE: @calvinklein
View source version on businesswire.com: https://www.businesswire.com/news/home/20200803005090/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 09:01:00 CEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 08:36:00 CEST | Press release
Discovered by Takeda in Japan, ORZEYFUL has the Potential to Redefine Care Beyond Individual Symptom Management for Adults Living with Narcolepsy Type 1 (NT1) Landmark Phase 3 Studies Demonstrated Significant and Meaningful Improvements Across the Full Range of NT1 Symptoms Evaluated in Clinical Trials Compared to Placebo Milestone Marks Third Major Regulatory Approval Secured for ORZEYFUL Around the World Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly
Fasset Hits $1B Valuation as SBI Group Leads $68M Series C to Scale AI-Powered Stablecoin Neobanking24.8.2026 08:03:00 CEST | Press release
Round led by SBI Group follows $51 million Series B raise in May 2026, marking ascent as one of the fastest-growing neobanking platforms. Capital will expand Own Network and deepen AI across stablecoin settlement, tokenization, and corridor banking. Fasset now processes more than $40 billion in annualized transaction volume, serving 3 million+ wallets and more than 1,000 enterprises across 125 countries. Fasset, the AI-powered stablecoin neobanking platform, today announced it has raised $68 million in Series C funding at a $1 billion valuation. The financing was led by SBI Group and follows Fasset’s $51 million Series B earlier this year, which brought Speedinvest onto the cap table alongside a group of strategic investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823503947/en/ Mohammad Raafi Hossain, Co-Founder and CEO, Fasset The new capital will support the expansion of Own Network, Fasset’s regulated financial
Zanders Expands DACH Region with New Office in Vienna, Austria24.8.2026 07:11:00 CEST | Press release
Zanders, the global treasury, risk, and technology consultancy, today announced a significant expansion of its DACH region with the opening of a new office in Vienna. The move builds on Zanders' continued growth across Germany, Austria, and Switzerland, and marks another step in the firm's strategy of deepening its presence in the markets where client demand for specialized treasury, risk, and corporate finance advisory is growing fastest. DACH has been one of Zanders' priority regions for several years, with the firm steadily expanding its team and client base across Germany and Switzerland. Austria represents a natural next step in that growth: in conversations with clients in the market, Zanders has seen growing interest in treasury transformation and financing support, as companies work through interest rate volatility, refinancing needs, and a broader shift toward more digitized, centralized treasury operations. The new Vienna office allows Zanders to be closer to clients' operati
Novotech Strengthens Presence in Japan with Opening of Tokyo Office24.8.2026 01:01:00 CEST | Press release
Novotech, a leading global biotech CRO and full-service clinical research organization, has strengthened its established presence in Japan with the opening of a new office in Tokyo. The investment builds on Novotech’s existing operations and clinical trial activity in Japan and further enhances its ability to support Japanese biopharma companies as they advance programs regionally and across key international markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260823592174/en/ Takeshi Mori, Novotech Country Head, Japan The Tokyo office will serve as a strategic hub for Novotech’s growing operations in Japan, providing enhanced local expertise and strengthening collaboration with clients, partners, research institutions, and innovation ecosystems across the region. Novotech is currently supporting ongoing studies in Japan and provides sponsors with integrated support across early-phase clinical development in Australia, F
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom